Boehringer Ingelheim Bolsters HCV Research Portfolio With Biota Deal
German firm will pay $102 mil. for rights to develop and commercialize Biota’s novel nucleoside analogues for hepatitis C.
German firm will pay $102 mil. for rights to develop and commercialize Biota’s novel nucleoside analogues for hepatitis C.